Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis

References

• NICERheumatoid Arthritis Consultation Document [Internet] Available at: www.nice.org.ukAccessed January 26, 2010
   Google Scholar
• OhsugiYKishimotoTThe recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritisExpert Opin Biol Ther2008866968118407769
   PubMed Web of Science ®Google Scholar
• OhsugiYRecent advances in immunopathophysiology of interleukin-6: An innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseasesBiol Pharm Bull2007302001200617978466
   PubMed Web of Science ®Google Scholar
• SatoKTsuchiyaMSaldanhaJReshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growthCancer Res1993538518568428365
   PubMed Web of Science ®Google Scholar
• MiharaMKasutaniKOkazakiMTocilizumab inhibits signal transduction mediated by both mIL-6R and soluble interleukin-6 receptor, but not by the receptors of other members of IL-6 cytokine familyInt Immunopharmacol200551731174016102523
   PubMed Web of Science ®Google Scholar
• NishimotoNMiyasakaNYamamotoKStudy of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): Significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapyMod Rheumatol200919121918979150
   PubMed Web of Science ®Google Scholar
• NishimotoNHashimotoJMiyasakaNStudy of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised, controlled trial of tocilizumabAnn Rheum Dis2007661162116717485422
   PubMed Web of Science ®Google Scholar
• JonesGSebbaAGuJComparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION studyAnn Rheum Dis201069889619297346
   PubMed Web of Science ®Google Scholar
• GenoveseMCMcKayJDNasonovELInterleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: Tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy studyArthritis Rheum2008582968298018821691
   PubMed Web of Science ®Google Scholar
• SmolenJSBeaulieuARubbert-RothAEffect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trialLancet200837198799718358926
   PubMed Web of Science ®Google Scholar
• KremerJLBlancoRBrzoskoMTocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate at 1 year: The LITHE studyArthritis Rheum2010 November 19. [Epub ahead of print]
   Google Scholar
• EmeryPKeystoneETonyHPIL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trialAnn Rheum Dis2008671516152318625622
   PubMed Web of Science ®Google Scholar
• YamanakaHTanakaYInoueEEfficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: Results from a retrospective study (REACTION study)Mod Rheumatol2010 October 16. [Epub ahead of print]
   Web of Science ®Google Scholar
• HirabayashiYIshiiTHarigaeHClinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practiceRheumatol Int2010301041104819701637
   PubMed Web of Science ®Google Scholar
• NishimotoNMiyasakaNYamamotoKKawaiSTakeuchiTAzumaJLong-term safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): Evidence of safety and efficacy in a 5-year extension studyAnn Rheum Dis2009681580158419019888
   PubMed Web of Science ®Google Scholar
• NishimotoNTakagiNAssessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: Subanalysis of the SATORI studyMod Rheumatol20102053954720617358
   PubMed Web of Science ®Google Scholar
• FunahashiKKoyanoSMiuraTHagiwaraTOkudaKMatsubaraTEfficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 levelMod Rheumatol20091950751219609487
   PubMed Web of Science ®Google Scholar
• SmolenJSAletahaDInterleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactantsArthritis Rheum201163435221204103
   PubMed Web of Science ®Google Scholar
• NishimotoNItoKTakagiNSafety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: Meta-analysis of six initial trials and five long-term extensionsMod Rheumatol20102022223220221663
   PubMed Web of Science ®Google Scholar
• Van VollenhovenRFKeystoneECFurieRBleschAWangCCurtisJRGastrointestinal safety in patients with rheumatoid arthritis treated with tocilizumab: Data from Roche clinical trials. Abstr 1613Arthritis Rheum200960SupplS602
   Google Scholar
• MainiRNTaylorPCSzechinskiJDouble-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexateArthritis Rheum2006542817282916947782
   PubMed Web of Science ®Google Scholar
• OldfieldVDhillonSPloskerGLTocilizumab: A review of its use in the management of rheumatoid arthritisDrugs20096960963219368420
   PubMed Web of Science ®Google Scholar
• Van VollenhovenRFScaliJJCurtisJRSafety of tocilizumab in patients with rheumatoid arthritis: Analysis of median of 3.1 years of treatment in long-term extension studiesPoster SAT0172 presented at the European League against Rheumatism Annual European Congress of RheumatologyRome, ItalyJune 16–19, 2010
   Google Scholar
• Van GamerenMMWillemsePHMulderNHEffects of recombinant human interleukin-6 in cancer patients: A phase I-II studyBlood199484143414418068939
   PubMed Web of Science ®Google Scholar
• WeberJYangJCTopalianSLPhase I trial of subcutaneous interleukin-6 in patients with advanced malignanciesJ Clin Oncol1993114995067680375
   PubMed Web of Science ®Google Scholar
• VisMNurmohamedMTWolbinkGShort term effects of infliximab on the lipid profile in patients with rheumatoid arthritisJ Rheumatol20053225225515693084
   PubMed Web of Science ®Google Scholar
• DursunoğluDEvrengülHPolatBLp(a) lipoprotein and lipids in patients with rheumatoid arthritis: Serum levels and relationship to inflammationRheumatol Int20052524124515290086
   PubMed Web of Science ®Google Scholar
• ChoyESattarNInterpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: A challenge to conventional cardiovascular risk actionsAnn Rheum Dis20096846046919286905
   PubMed Web of Science ®Google Scholar
• HashizumeMYoshidaHKoikeNSuzukiMMiharaMOverproduced interleukin 6 decreases blood lipid levels via upregulation of very- low-density lipoprotein receptorAnn Rheum Dis20106974174619433409
   PubMed Web of Science ®Google Scholar
• PopaCNeteaMGRadstakeTInfluence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritisAnn Rheum Dis20056430330515231512
   PubMed Web of Science ®Google Scholar
• HoussiauFADevogelaerJPVan DammeJde DeuxchaisnesCNVan SnickJInterleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritidesArthritis Rheum1988317847883260102
   PubMed Web of Science ®Google Scholar
• MadhokRCrillyAWatsonJCapellHASerum interleukin 6 levels in rheumatoid arthritis: Correlations with clinical and laboratory indices of disease activityAnn Rheum Dis1993522322348484679
   PubMed Web of Science ®Google Scholar
• AkiraSTagaTKishimotoTInterleukin-6 in biology and medicineAdv Immunol1993541788379461
   PubMed Web of Science ®Google Scholar
• MaruottiNCantatoreFPCrivellatoEVaccaARibattiDAngiogenesis in rheumatoid arthritisHistol Histopathol20062155756616493585
   PubMed Web of Science ®Google Scholar
• NakaharaHSongJSugimotoMAnti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritisArthritis Rheum2003481521152912794819
   PubMed Web of Science ®Google Scholar
• HashizumeMHayakawaNSuzukiMMiharaMIL-6/soluble interleukin-6 receptor trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture systemRheumatol Int2009291449145419277666
   PubMed Web of Science ®Google Scholar
• UchiyamaYYorozuKHashizumeMMoriyaYMiharaMTocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritisBiol Pharm Bull2008311159116318520048
   PubMed Web of Science ®Google Scholar
• SuzukiMHashizumeMYoshidaHMiharaMAnti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: Effect on the expression of chemokine and adhesion moleculeRheumatol Int20103030931519466425
   PubMed Web of Science ®Google Scholar
• MiharaMMoriyaYKishimotoTOhsugiYInterleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptorBr J Rheumatol1995343213257788145
   PubMedGoogle Scholar
• HashizumeMHayakawaNMiharaMIL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17Rheumatology (Oxford)2008471635164018786965
   PubMed Web of Science ®Google Scholar
• SagawaAThe effect of short term treatment of anti-IL-6 receptor antibody tocilizumab on signs and symptoms and synovial inflammation in patients with active rheumatoid arthritisAnn Rheum Dis201069Suppl 3539
   Google Scholar
• FujikawaYShinguMTorisuTItonagaIMasumiSBone resorption by tartrate-resistant acid phosphatase-positive multinuclear cells isolated from rheumatoid synoviumBr J Rheumatol1996352132178620294
   PubMedGoogle Scholar
• GravalleseEMManningCTsayASynovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factorArthritis Rheum20004325025810693863
   PubMed Web of Science ®Google Scholar
• LaceyDLTimmsETanHLOsteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activationCell1998931651769568710
   PubMed Web of Science ®Google Scholar
• KongYYYoshidaHSarosiIOPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesisNature19993973153239950424
   PubMed Web of Science ®Google Scholar
• TakayanagiHIizukaHJujiTInvolvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritisArthritis Rheum20004325926910693864
   PubMed Web of Science ®Google Scholar
• CohenSBDoreRKLaneNEDenosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trialArthritis Rheum2008581299130918438830
   PubMed Web of Science ®Google Scholar
• HashizumeMMiharaMDesirable effect of combination therapy with high molecular weight hyaluronate and nonsteroidal anti-inflammatory drugs on MMP productionOsteoarth Cartil20091715131518
   PubMed Web of Science ®Google Scholar
• SuzukiMHashizumeMYoshidaHShiinaMMiharaMIL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor I expressionCytokine20105117818320403707
   PubMed Web of Science ®Google Scholar
• HashimotoJGarneroPvan der HeijdeDHumanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: Data from the SAMURAI studyMod Rheumatol6242010 [Epub ahead of print]
   Web of Science ®Google Scholar
• GarneroPThompsonEWoodworthTSmolenJSRapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexateArthritis Rheum201062334320039425
   PubMed Web of Science ®Google Scholar
• KawashiriSYKawakamiAIwamotoNSwitching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologicsMod Rheumatol201020404519802651
   PubMed Web of Science ®Google Scholar
• BaerANDessyprisENGoldwasserEKrantzSBBlunted erythropoietin response to anemia in rheumatoid arthritisBr J Haematol1987665595643663512
   PubMed Web of Science ®Google Scholar
• HochbergMCArnoldCMHogansBBSpivakJLSerum immuno-reactive erythropoietin in rheumatoid arthritis: Impaired response to anemiaArthritis Rheum198831131813213178910
   PubMed Web of Science ®Google Scholar
• Jongen-LavrencicMPeetersHRWognumAVreugdenhilGBreedveldFCSwaakAJElevated levels of inflammatory cytokines in bone marrow of patients with rheumatoid arthritis and anemia of chronic diseaseJ Rheumatol199724150415099263142
   PubMed Web of Science ®Google Scholar
• VoulgariPVKoliosGPapadopoulosGKKatsarakiASeferiadisKDrososAARole of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritisClin Immunol19999215316010444359
   PubMed Web of Science ®Google Scholar
• UchiyamaYKoikeNMiharaMAnemia in monkey collagen-induced arthritis is correlated with serum IL-6, but not TNF alphaRheumatol Int20082887988318309490
   PubMed Web of Science ®Google Scholar
• GanzTHepcidin, a key regulator of iron metabolism and mediator of anemia of inflammationBlood200310278378812663437
   PubMed Web of Science ®Google Scholar
• RiveraSNemethEGabayanVLopezMAFarshidiDGanzTSynthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organsBlood20051062196219915933050
   PubMed Web of Science ®Google Scholar
• NicolasGBennounMPorteuASevere iron deficiency anemia in transgenic mice expressing liver hepcidinProc Natl Acad Sci U S A2002994596460111930010
   PubMed Web of Science ®Google Scholar
• NemethERiveraSGabayanVIL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidinJ Clin Invest20041131271127615124018
   PubMed Web of Science ®Google Scholar
• HashizumeMUchiyamaYHoraiNTomosugiNMiharaMTocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin productionRheumatol Int20103091792319639319
   PubMed Web of Science ®Google Scholar
• BettelliECarrierYGaoWReciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature200644123523816648838
   PubMed Web of Science ®Google Scholar
• IwanamiKMatsumotoITanaka-WatanabeYCrucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomeraseArthritis Rheum20085875476318311788
   PubMed Web of Science ®Google Scholar
• FujimotoMSeradaSMiharaMInterleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responsesArthritis Rheum2008583710371919035481
   PubMed Web of Science ®Google Scholar
• YoshidaHHashizumeMMiharaMIL-6 blockade preferentially inhibits Th17 differentiation in collagen-induced arthritisRheumatol Int20113112713120658238
   PubMed Web of Science ®Google Scholar
• NotleyCAInglisJJAlzabinSMcCannFEMcNameeKEWilliamsROBlockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cellsJ Exp Med20082052491249718936235
   PubMed Web of Science ®Google Scholar
• AnnunziatoFCosmiLLiottaFMaggiERomagnaniSThe phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammationInt Immunol2008201361136818820263
   PubMed Web of Science ®Google Scholar
• ZhangCZhangJYangBWuCCyclosporin A inhibits the production of IL-17 by memory Th17 cells from healthy individuals and patients with rheumatoid arthritisCytokine20084234535218424069
   PubMed Web of Science ®Google Scholar
• PapagorasCVoulgariCVDrososAAStrategies after the failure of the first anti-tumor necrosis factor α agent in rheumatoid arthritisAutoimmun Rev2010957458220433955
   PubMed Web of Science ®Google Scholar
• RadstakeTRSvensonMEijsboutsAMFormation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritisAnn Rheum Dis2009681739174519019895
   PubMed Web of Science ®Google Scholar
• BongartzTSuttonAJSweetingMJBuchanIMattesonELMontoriVAnti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trialsJ Am Med Assoc200629522752285
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Subcommittee on Rheumatoid Arthritis GuidelinesGuidelines for the management of rheumatoid arthritis: 2002 updateArthritis Rheum20024632834611840435
   PubMed Web of Science ®Google Scholar
• OkudaYTakasugiKSuccessful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritisArthritis Rheum2006542997300016947531
   PubMed Web of Science ®Google Scholar
• HusbyGTreatment of amyloidosis and the rheumatologist. State of the art and perspectives for the futureScand J Rheumatol1998271611659645409
   PubMed Web of Science ®Google Scholar
• Del RincónIDWilliamsKSternMPFreemanGLEscalanteAHigh incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factorsArthritis Rheum2001442737274511762933
   PubMed Web of Science ®Google Scholar
• HagiharaKNishikawaTIsobeTSongJSugamataYYoshizakiKIL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay systemBiochem Biophys Res Commun200431436336914733913
   PubMed Web of Science ®Google Scholar
• Van VollenhovenRFNishimotoNYamanakaHExperience with mycobacterium tuberculosis infection reported in the tocilizumab worldwide RA safety databaseAnn Rheum Dis200968Suppl 3557
   Google Scholar
• OgataAMoriMHashimotoSMinimal influence of tocilizumab on IFN-gamma synthesis by tuberculosis antigensMod Rheumatol20102013013319898919
   PubMed Web of Science ®Google Scholar
• OhsugiYKishimotoTThe recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritisExpert Opin Biol Ther2008866968118407769
   PubMed Web of Science ®Google Scholar